Friday, February 23, 2024
HomeRecent Articles Torino-based Resalis Secures €10 Million in Series A Round Funding

[Funding alert] Torino-based Resalis Secures €10 Million in Series A Round Funding

Torino-based Resalis secures €10 million in series A round funding. This round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors.

Torino-based Resalis secures €10 million in series A round funding. This round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors.

The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program, RES-010, in obesity.

Read also – UK-based Technology Company Travelport Secures $570m in New Equity Funding

RES-010 is a non-coding RNA-based compound designed to provide a disease-modifying approach in obesity with longer-lasting weight reduction and the ability to extend treatment durability in combination with approved therapeutics, such as GLP-1 receptor agonists. In conjunction with the financing, Claus Andersson, PhD, General Partner of Sunstone Life Science Ventures, will join Resalis’ Board of Directors.

Alessandro Toniolo, CEO of Resalis Therapeutics said, “The successful close of our Series A is an important milestone for Resalis because it will enable us to reach the clinic and to achieve the next significant inflection point with our lead candidate, RES-010. With RES-010 we aim to provide a therapeutic that precisely reduces fat mass in obesity with the potential to extend the durability of existing therapies. We value the trust and support of our new and current investors, and eagerly look forward to this next phase of development,”

Claus Andersson, General Partner at Sunstone Life Science Ventures said, “Resalis’ therapeutic approach is based on groundbreaking science that has rapidly led to the
development of a lead candidate, now on the cusp of clinical evaluation. Preserving muscle mass is key to provide a sustained and meaningful clinical benefit, and we share the team’s vision that this non-GLP1/GIP therapeutic will significantly improve both effect and tolerability of today’s therapies. This investment underscores our belief in the company’s vision and the transformative potential of its lead candidate to make a meaningful impact for obese patients,”.

Pietro Puglisi, Managing Partner at Claris Ventures and Chairman of the Board at Resalis Therapeutics, added: “In recent years, there has been remarkable progress in the treatment of metabolic disorders. Yet, there persists a critical need for innovative solutions that can both provide orthogonal therapeutic effects and pave the way for combination therapies. I look forward to the continued collaboration with the outstanding Resalis team and welcoming Claus as a new member of the Resalis Board.”

About Resalis Therapeutics

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Read also – Lyon-based ENYO Pharma Secures a €39 Million in Series C Round Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular